

## The right antibiotics – right on time

### Investment Rational

phenofAST is disrupting antibiotic testing by reducing turnaround from 3 days to 4 hours. The current long turnaround is forcing physicians to prescribe antibiotic empirically with 50% error rate, inadvertently boosting the prevalence of antimicrobial resistance (AMR) - accountable for 1.2M deaths/year and increasing healthcare costs. phenofAST technology takes only 4 hours for testing the susceptibility of bacteria to multiple instances of antibiotic types, a key in preventing mistreatment-related health complications, shortening hospital's stay, and reducing medical expenses.

### Business Strategy

Our revenues are based on sales of disposable test kits that are used with our devices. The value proposition is driven from reducing the healthcare costs associated with 3M annual AMR patients and 250K antibiotic-misuse adverse reactions in the US alone.

### Core Technology

phenofAST has developed a new technology for label-free optical detection by tracing the accurate and low variance intrinsic photonic properties of the bacteria.

Competing technologies are based on traditional concepts i.e., *microscopy*, *molecular labeling*, or *metabolic markers*, which are all limited by the high variance enforced by bacteria inherent evasiveness.

### Product Profile/Pipeline

Fully automatic laboratory diagnostic device, with 4 hours turnaround time. Our initial application target Urinary tract infections with \$2B potential in US markets. Product pipeline includes additional indications, most notably circulatory and respiratory infections increasing US market potential over \$5B.

### What's Next?

The company has demonstrated its first prototype and is conducting on-going clinical validation in collaboration with Emek medical center, Israel.

R&D: Conduct clinical investigations and improve hardware functionality and algorithm efficiency

Clinicals: Conduct clinical trials in US/EU laboratories